More tools:Markets·Screener·Research·Chat

CervoMed Inc. Common Stock (CRVO) Financial Statements

CervoMed Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SD4Z42
XNAS · usd
2.53▲ 0.00 (0.00%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close2.53
Day's Range2.42 – 2.58
52-Week Range2.13 – 10.59
Volume392.6K
Avg Volume309.0K
Share Statistics
Shares Outstanding
Employees15
ExchangeXNAS
Listed1996-06-18
Share count as of August 6, 2026
Loading Income Statement…
Key questions about CervoMed Inc. Common Stock (CRVO)
What is CervoMed Inc. Common Stock's Market Cap?
CervoMed Inc. Common Stock's Market Cap is $38.3M, based on as-reported figures from SEC (XBRL) filings.
What is CervoMed Inc. Common Stock's Enterprise Value?
CervoMed Inc. Common Stock's Enterprise Value is $13.3M, based on as-reported figures from SEC (XBRL) filings.
What is CervoMed Inc. Common Stock's Price / Sales?
CervoMed Inc. Common Stock's Price / Sales is 115.5×, based on as-reported figures from SEC (XBRL) filings.
What is CervoMed Inc. Common Stock's EV / Revenue?
CervoMed Inc. Common Stock's EV / Revenue is 40.2×, based on as-reported figures from SEC (XBRL) filings.
What is CervoMed Inc. Common Stock's Revenue (TTM)?
CervoMed Inc. Common Stock's Revenue (TTM) is $331.3K, based on as-reported figures from SEC (XBRL) filings.
What is CervoMed Inc. Common Stock's Net Income (TTM)?
CervoMed Inc. Common Stock's Net Income (TTM) is -$30.3M, based on as-reported figures from SEC (XBRL) filings.
What is CervoMed Inc. Common Stock's Diluted EPS (TTM)?
CervoMed Inc. Common Stock's Diluted EPS (TTM) is -2.01, based on as-reported figures from SEC (XBRL) filings.
What is CervoMed Inc. Common Stock's Net Debt?
CervoMed Inc. Common Stock's Net Debt is -$24.9M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Grant revenue
YoY growth-100.0%-100.0%-99.6%-83.4%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue——95579.2%2593.8%
Loss from operations
% of revenue——-95479.2%-2493.8%
Other income (expense):
Other expense
Interest income
Total other income, net
Net loss
% of revenue——-92680.4%-2395.3%
Net loss per share of common stock, basic and diluted (in dollars per share)